Home / Stocks / Syngene International Ltd
SYNGENE

Syngene International Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹437.35

Change

+2.55 (0.59%)

Open

₹434.8

Prev. Close

₹434.8

Day High

₹438.95

Day Low

₹430.15

Volume Analysis

Traded

219,151

Delivered

106,280

Delivery %

48.5%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (21.0%)

Weaknesses (2)

  • •Low return on equity (7.78%)
  • •Promoter holding is falling

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹449.61 ₹444.28 ₹440.81 ₹435.48 ₹432.01 ₹426.68 ₹423.21
Fibonacci ₹444.28 ₹440.92 ₹438.84 ₹435.48 ₹432.12 ₹430.04 ₹426.68
Camarilla ₹439.77 ₹438.96 ₹438.16 ₹435.48 ₹436.54 ₹435.74 ₹434.93

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-32.74%

1 Week

-2.33%

1 Month

+16.18%

3 Months

+7.39%

6 Months

-5.3%

1 Year

-31.08%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹145.68

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

4.05%

Net margin 5.28% × asset turnover 0.56x × equity multiplier 1.37x

Company Overview

Sector

Healthcare

Market Cap

₹17,935 Cr

P/E (TTM)

67.5

ROE

7.78%

Book Value

₹120.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Syngene International Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 55/100. The strongest factor is Financial Strength (100/100), while Growth (21/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (21.0%); low return on equity (7.78%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

55/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

21

Valuation

26

Cash Flow

96

Corporate Governance

70

Momentum

30

Institutional Ownership

59

Business Quality

56

Risk & Volatility

41

Liquidity

51

From Screener.in

  • −Stock is trading at 3.69 times its book value
  • −The company has delivered a poor sales growth of 11.4% over past five years.
  • −Company has a low return on equity of 10.2% over last 3 years.
  • −Dividend payout has been low at 12.0% of profits over last 3 years

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Syngene schedules analyst/investor meetings with several institutions from 17-24 Nov 2026.

Syngene uploaded Q2 FY2027 earnings conference call transcript on its website.

Audio recording of Syngene’s Q2 FY27 earnings call uploaded on October 28, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 910 854 917 790 891 944 1,018 874 911 917 1,036 736 833
Expenses + 656 622 600 620 646 660 674 668 711 708 733 645 685
Operating Profit 254 232 317 170 245 284 344 206 200 209 303 91 147
OPM % 28.0% 27.0% 35.0% 22.0% 27.0% 30.0% 34.0% 24.0% 22.0% 23.0% 29.0% 12.0% 18.0%
Other Income + 14 26 16 50 16 18 19 18 15 -55 16 12 21
Interest 13 11 13 12 13 12 16 12 13 12 12 10 10
Depreciation 105 108 111 107 111 109 106 111 116 114 112 112 112
Profit before tax 151 138 209 101 137 181 240 101 85 28 196 -19 47
Tax % 23.0% 19.0% 10.0% 25.0% 23.0% 27.0% 24.0% 14.0% 21.0% 47.0% 25.0% -53.0% 31.0%
Net Profit + 116 112 189 76 106 131 183 87 67 15 148 -9 32
EPS in Rs 3 3 5 2 3 3 5 2 2 0 4 0 1
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 18 9 -8 -2 -2 11 11 11 2 -3 2 -16 -9

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 1,423 1,826 2,012 2,184 2,604 3,193 3,489 3,642 3,739 3,522
Expenses + 949 1,289 1,394 1,507 1,861 2,251 2,472 2,598 2,817 2,772
Operating Profit 474 537 618 678 743 942 1,017 1,045 921 751
OPM % 33.0% 29.0% 31.0% 31.0% 29.0% 30.0% 29.0% 29.0% 25.0% 21.0%
Other Income + 53 75 153 94 75 63 77 101 -9 -6
Interest 23 32 35 28 24 45 47 53 49 44
Depreciation 131 164 219 274 310 366 426 433 453 449
Profit before tax 372 415 517 469 484 594 621 660 411 252
Tax % 18.0% 20.0% 20.0% 14.0% 18.0% 22.0% 18.0% 25.0% 23.0% —
Net Profit + 305 332 412 405 396 464 510 496 317 186
EPS in Rs 8 8 10 10 10 12 13 12 8 5
Dividend Payout % 7.0% 3.0% 0.0% 0.0% 10.0% 11.0% 10.0% 10.0% 16.0% —
Sales growth — 28 10 9 19 23 9 4 3 -6

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 1,520 1,768 1,776 2,421 2,897 3,217 3,856 4,324 4,436 4,455
Borrowings + 787 813 773 893 1,022 815 555 578 458 507
Other Liabilities + 681 922 1,214 1,169 1,245 1,398 1,339 1,491 1,757 1,292
Total Liabilities 3,189 3,704 4,163 4,883 5,564 5,831 6,152 6,796 7,055 6,658
Fixed Assets + 1,030 1,377 2,020 2,201 2,393 2,667 2,850 2,802 3,000 2,880
CWIP 155 274 234 237 346 177 838 1,266 1,046 1,141
Investments 158 716 776 702 1,034 918 548 647 741 610
Other Assets + 1,846 1,337 1,133 1,743 1,790 2,069 1,916 2,081 2,268 2,028
Total Assets 3,189 3,704 4,163 4,883 5,564 5,831 6,152 6,796 7,055 6,658
Equity Capital 200 200 400 400 401 401 402 402 403 404

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 446 630 677 701 581 824 1,042 1,168 915
Cash from Investing Activity + -349 -646 -424 -629 -611 -653 -494 -744 -839
Cash from Financing Activity + -79 -72 -226 58 -31 -342 -551 -142 -215
Net Cash Flow 18 -88 28 130 -62 -172 -4 281 -138
Free Cash Flow 82 47 34 255 105 305 553 398 547
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 111 135 127 116 92 102 115 123 107

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 54.79% → 52.59%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Others 0.32% 0.31% 0.43% 0.34% 0.29% 0.29% 0.31% 0.3% 0.29% 0.29% 0.43% 0.41%
Public 9.07% 8.18% 7.44% 6.74% 6.79% 5.99% 6.45% 6.08% 6.22% 6.69% 7.15% 7.55%
Promoters 54.79% 54.79% 54.72% 54.72% 52.74% 52.74% 52.68% 52.68% 52.68% 52.68% 52.59% 52.59%
FII 21.2% 20.92% 20.64% 20.72% 20.65% 19.47% 16.51% 16.31% 14.96% 13.91% 11.82% 10.13%
DII 14.63% 15.8% 16.78% 17.49% 19.52% 21.5% 24.05% 24.62% 25.83% 26.44% 28.01% 29.31%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Syngene International Ltd (this stock) 17,935 67.5 3.7 7.78%
Caplin Point Lab Ltd. 17,863 25.9 4.58 20.9%
Alivus Life Sciences Ltd 17,803 50.6 — —
Pfizer Ltd 17,601 115.0 12.74 19.8%
Cohance Lifesciences Ltd 17,511 359.0 4.49 4.89%
Dr Agarwals Health Care L 17,460 97.5 7.8 6.41%
Eris Lifesciences Limited 18,448 24.7 4.45 18.7%

Which Mutual Funds Hold Syngene International Ltd?

Frequently Asked Questions about Syngene International Ltd

Community Sentiment

What are other investors saying about Syngene International Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.